|
About:
|
Microsatellite uncertainty (MSI-H) is assigned to a high immunoscore and not with PD-L1 appearance or increased success inside individuals (pts.) along with metastatic intestines cancer (mCRC) addressed with oxaliplatin (oxen) along with fluoropyrimidine (FP) with and also with no bevacizumab (bev): the pooled research AIO KRK 0207 and also RO91 studies.
|